Eli Lilly and Company (NYSE:LLY) Shares Down 3.5% – What’s Next?

Eli Lilly and Company (NYSE:LLY) fell 3.5% on Thursday. The company traded as low as $1,364.73 and last traded at $1,368.8480. 4,754,317 shares changed hands during mid-day trading, an increase of 61% from the average daily volume of 2,955,016 shares. The stock had previously closed at $1,417.99.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly said new Phase 3 results for investigational retatrutide showed substantial weight and knee-pain reductions in adults with obesity and knee osteoarthritis. Phase 3b data also showed benefits from combining Taltz and Zepbound for people with psoriatic arthritis and obesity. The findings support the potential of its obesity and broader treatment pipeline. Lilly ACR data announcement
• Positive Sentiment: The recent quarterly results beat analyst estimates, with revenue up 38.6% year over year, and Lilly raised its 2026 revenue outlook. This strong performance has helped underpin optimism about continued demand for its medicines. Weight-loss drug growth outlook
• Neutral Sentiment: Lilly is presenting updates on its cancer pipeline, including an early-stage imlunestrant study and a completed gastric-cancer study. The reports signal ongoing research, but the supplied details do not establish a material change in clinical prospects. Imlunestrant study update
• Negative Sentiment: Investor commentary highlights rising price competition for Lilly’s GLP-1 franchise. Concerns about lower realized drug prices and the durability of growth could pressure expectations, particularly with the shares trading at a premium valuation. GLP-1 price competition commentary

Wall Street Analysts Forecast Growth

Several analysts have commented on LLY shares. Cantor Fitzgerald increased their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a research note on Monday. Sanford C. Bernstein restated an “outperform” rating and issued a $1,450.00 price target on shares of Eli Lilly and Company in a research note on Monday, October 26th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Leerink Partners upped their price target on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a report on Wednesday, October 21st. Finally, JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,404.14.

Eli Lilly and Company Stock Down 3.5%

The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The company’s fifty day moving average is $1,207.75 and its 200-day moving average is $1,097.85. The company has a market cap of $1.29 trillion, a PE ratio of 44.43, a PEG ratio of 1.76 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm’s revenue was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $7.02 EPS. On average, analysts predict that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is presently 22.46%.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,500 shares of company stock valued at $22,970,770 over the last 90 days. Company insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors have recently made changes to their positions in the business. Marshall & Sterling Wealth Advisors Inc. lifted its position in shares of Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after buying an additional 15 shares in the last quarter. Torren Management LLC grew its stake in shares of Eli Lilly and Company by 357.1% during the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after acquiring an additional 25 shares during the period. AlphaCentric Advisors LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $42,000. Foresight Capital Management Advisors Inc. purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $49,000. Finally, Caitlin John LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $64,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.